Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer

Abstract

<jats:title>Abstract</jats:title><jats:p>The dysregulation of RNA binding proteins (RBPs) play critical roles in the progression of several cancers. However, the overall functions of RBPs in prostate cancer (PCa) remain poorly understood. Therefore, we first identified 144 differentially expressed RBPs in tumors compared to normal tissues based on the TCGA dataset. Next, six RBP genes (MSI1, MBNL2, LENG9, REXO2, RNASE1, PABPC1L) were screened out as prognosis hub genes by univariate, LASSO and multivariate Cox regression and used to establish the prognostic signature. Further analysis indicated that high risk group was significantly associated with poor RFS, which was validated in the MSKCC cohort. Besides, patients in high risk group was closely associated with dysregulation of DNA damage repair pathway, copy number alteration, tumor burden mutation and low-respond to cisplatin (P &lt; 0.001), bicalutamide (P &lt; 0.001). Finally, three drugs (ribavirin, carmustine, carbenoxolone) were predicted using Connectivity Map. In summary, we identified a six-RBP gene signature and three candidate drugs against PCa, which may promote the individualized treatment and further improve the life quality of PCa patients.</jats:p>

Integrated Multi-Omics Data Reveals the Molecular Subtypes of Prostate Cancer

“…The dysfunction of RNA binding proteins (RBPs) in tumorigenesis is important as well. Our prior work constructed RFS-associated RBPs and generated a prognostic signature to help identify patients with high risk and resistance to ARSI 37 .…”